Literature DB >> 2172569

Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy.

J P Richie1.   

Abstract

A total of 85 patients underwent modified retroperitoneal lymphadenectomy for clinical stage I nonseminomatous germ cell tumor of the testis from 1982 to 1989. The technique was a modified bilateral dissection via a thoracoabdominal approach. A full bilateral dissection was done above the level of the inferior mesenteric artery but unilateral dissection was performed below the inferior mesenteric artery using a template method. Of the 85 patients 64 had pathological stage A and 21 had stage B1 disease. Relapses have occurred in 4 of 64 stage A cancer patients (6%) and 3 of 21 stage B1 cancer patients (15%). Antegrade ejaculation was preserved without pharmacological therapy in 75 of 85 patients (88%) and 5 others were converted to antegrade ejaculation with imipramine. Therefore, 80 of 85 patients (94%) have recovered antegrade ejaculation. With a median followup of 38 months 7 relapses have been noted. We conclude that modified retroperitoneal lymph node dissection allows for preservation of ejaculation, decreases concern about retroperitoneal understaging and represents the preferred alternative to surveillance protocols for patients with low stage testicular cancer.

Entities:  

Mesh:

Year:  1990        PMID: 2172569     DOI: 10.1016/s0022-5347(17)39681-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 2.  The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates.

Authors:  Mark H Katz; Scott E Eggener
Journal:  World J Urol       Date:  2009-04-11       Impact factor: 4.226

Review 3.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 4.  Retroperitoneal lymph node dissection: an update in testicular malignancies.

Authors:  K Yadav
Journal:  Clin Transl Oncol       Date:  2017-02-01       Impact factor: 3.405

Review 5.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 6.  Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.

Authors:  Roy Mano; Renzo Di Natale; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

7.  Iatrogenic damage to male reproductive function.

Authors:  W F Hendry
Journal:  J R Soc Med       Date:  1995-10       Impact factor: 5.344

Review 8.  Controversies in the management of stage 1 non-seminomatous germ cell tumors.

Authors:  Sarah Coleman; Andrew Stephenson
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 9.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

10.  Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

Authors:  J Lee Villano; Jennifer M Propp; Kimberly R Porter; Andrew K Stewart; Tibor Valyi-Nagy; Xinyu Li; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.